Clinical Trials
162 trialsCHRU-WCMC
University Hospital, Lille
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Association Between Irrigation Fluid Absorption and Perioperative cfDNA Dynamics After TURBT
Lanzhou University Second Hospital
MRG003
Sun Yat-sen University
CISTO
University of Washington
MEVPRO-1
Pfizer
TVNIM-AFU
Association Francaise d'Urologie
Safety and Tolerability of ²¹²Pb-DOTAM-GRPR1 in Adult Subjects With Recurrent or Metastatic GRPR-expressing Tumors
Orano Med LLC
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
Regeneron Pharmaceuticals
JIVAN
Aurigene Discovery Technologies Limited
A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
IDEAYA Biosciences
LUTEON
Telix Pharmaceuticals (Innovations) Pty Limited
DutaBCa-1
CHU de Quebec-Universite Laval
STARTRK-NG
Hoffmann-La Roche
MIDAS-Prostate
University Health Network, Toronto
EVER
Verity Pharmaceuticals Inc.
Radiomics of Treatment-naive Prostate Cancer Patients on Multiparametric MRI for Risk Stratification and Treatment Outcomes Predictions
Chang Gung Memorial Hospital
A Study To Evaluate The Efficacy And Safety Of Ifinatamab Deruxtecan (I-DXd) In Subjects With Recurrent Or Metastatic Solid Tumors (IDeate-PanTumor02)
Daiichi Sankyo
CRUCIAL-R
S. Andrea Hospital
Comparison of Pathological Outcome and Recurrence Rate Between En Bloc and Conventional Transurethral Resection of Bladder Tumor
Lahore General Hospital
ON-5001
OncoNano Medicine, Inc.
Study With ABBV-CLS-484 in Participants With Locally Advanced or Metastatic Tumors
Calico Life Sciences LLC
SWENOTECA-ABC
St. Olavs Hospital
KP-CARAIBES
Centre Hospitalier Universitaire de la Guadeloupe
GuidePath
Novartis
COBRA-NMIBC
Aarhus University Hospital
GEM-IR-NMIBC
Shanghai University of Traditional Chinese Medicine
AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)
Arsenal Biosciences, Inc.
Add-Aspirin: A Trial Assessing the Effects of Aspirin on Disease Recurrence and Survival After Primary Therapy in Common Non Metastatic Solid Tumours
University College, London
Anesthesia Modality and Oncologic Outcomes in High-Risk NMIBC: A Randomized Trial
National Taiwan University Hospital
FocaSaBra
The Greater Poland Cancer Centre
uTRACT
UroGen Pharma Ltd.
CRYO-BO-2021
IRCCS Azienda Ospedaliero-Universitaria di Bologna
PREPARE
AIO-Studien-gGmbH
Health Care Coach Support in Reducing Acute Care Use and Cost in Patients With Cancer
Stanford University
A Pilot Study of Thermodox and MR-HIFU for Treatment of Relapsed Solid Tumors
Children's National Research Institute
MK-6482-003
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
CheckMate 914
Bristol-Myers Squibb
Hippocampal Sparing Whole Brain Radiation Versus Stereotactic Radiation in Patients With 5-20 Brain Metastases: A Phase III, Randomized Trial
Dana-Farber Cancer Institute
Prediction of Local Recurrence and Its Impact on Long-term Outcomes After Low-risk Glans-sparing Surgery for Penile Squamous Cell Carcinoma
Universitaire Ziekenhuizen KU Leuven
The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma
Wuhan Ammunition Life-tech Co., Ltd
A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder Cancer
Altor BioScience
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
M.D. Anderson Cancer Center
ProCaB
Universitaire Ziekenhuizen KU Leuven
Biomarkers of Recurrence and Progression in Non-muscle Invasive Bladder Cancer
Wroclaw Medical University
Determination of the Diagnostic Detection Rate of Axumin (Fluciclovine) Digital PET/CT, Post-prostatectomy
University of Vermont
GTN
Queen's University
HETERERO
Charite University, Berlin, Germany
A Dose Escalation and Expansion Study of TRX518 in Combination With Cyclophosphamide Plus Avelumab in Advanced Solid Tumors
Leap Therapeutics, Inc.
Kidney Cancer Observational Protocol
IRCCS San Raffaele